SGLT2 inhibitors have been proven to have good metabolic characteristics [30] and can substantially reduce atherosclerosis events, hospitalization due to heart failure and cardiovascular diseases, total mortality, and the progress of chronic kidney diseases [31, 32]. The gene discussed is SLC5A2; the disease is chronic kidney disease.